Supreme Court Ties On FDA Pre-Emption; Congress Seeks To Resolve Issue

Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval